Overview

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Status:
Completed

Trial end date:
2019-06-18

Target enrollment:

Participant gender:

Summary

The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.

Phase:

Phase 2

Details

Lead Sponsor:

Ipsen

Treatments:

Angiopeptin
Dacarbazine
Lanreotide
Somatostatin
Temozolomide